Home ETF List About

Portfolio Holdings Detail for ISIN IE00BHZPJ890
Stock Name / FundiShares MSCI USA ESG Enhanced UCITS ETF USD (Dist)
IssuerBlackrock
Entity holding fund iShares IV Public Limited Company
Entity Type
Entity LEI 549300ZP07LMR36K1T02
ETF TickerEEDG(GBP) LSE
ETF TickerEEDS(USD) LSE
ETF TickerEEDG.LS(GBP) CXE
ETF TickerEEDS.LS(USD) CXE
ETF TickerOM3L.DE(EUR) CXE
ETF TickerEEDG.L(GBP) LSE
ETF TickerEEDS.L(GBP) LSE

Holdings detail for INCY

Stock NameIncyte Corporation
TickerINCY(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS45337C1027
LEI549300Z4WN6JVZ3T4680

Show aggregate INCY holdings

News associated with INCY

Incyte Reaches Analyst Target Price
In recent trading, shares of Incyte Corporation (Symbol: INCY) have crossed above the average analyst 12-month target price of $84.18, changing hands for $84.80/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on v - 2025-09-18 08:17:02
Incyte Reports Encouraging 24-Week Results From Phase 3 STOP-HS Program Of Povorcitinib
(RTTNews) - Incyte Corporation (INCY) on Wednesday announced encouraging 24-week data from the pivotal Phase 3 STOP-HS program evaluating povorcitinib in adults with hidradenitis suppurativa (HS). - 2025-09-17 03:26:09
Incyte Corporation (NASDAQ:INCY) Short Interest Update
Incyte Corporation (NASDAQ:INCY – Get Free Report) was the recipient of a significant increase in short interest during the month of August. As of August 15th, there was short interest totaling 9,600,000 shares, an increase of 29.4% from the July 31st total of 7,420,000 shares. Based on an average trading volume of 1,860,000 shares, the […] - 2025-09-11 04:51:36
Incyte Corporation (NASDAQ:INCY) Receives Consensus Recommendation of “Hold” from Analysts
Incyte Corporation (NASDAQ:INCY – Get Free Report) has been assigned a consensus recommendation of “Hold” from the eighteen analysts that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating and seven have issued a buy rating on the company. The […] - 2025-08-26 02:32:54
Incyte (NASDAQ:INCY) Given New $73.00 Price Target at JPMorgan Chase & Co.
Incyte (NASDAQ:INCY – Free Report) had its price objective increased by JPMorgan Chase & Co. from $67.00 to $73.00 in a report issued on Friday,Benzinga reports. The brokerage currently has a neutral rating on the biopharmaceutical company’s stock. A number of other research firms also recently commented on INCY. Citigroup upped their price objective on […] - 2025-08-25 03:08:46
LABU, INCY, UTHR, REGN: ETF Outflow Alert
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Direxion Daily S&P Biotech Bull 3x Shares (Symbol: LABU) where we have detected an approximate $67.3 million dollar outflow -- that's a 9.4% dec - 2025-08-20 12:04:03
Charles Schwab Investment Management Inc. Purchases 38,962 Shares of Incyte Corporation (NASDAQ:INCY)
Charles Schwab Investment Management Inc. raised its position in shares of Incyte Corporation (NASDAQ:INCY – Free Report) by 2.4% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,682,029 shares of the biopharmaceutical company’s stock after purchasing an additional 38,962 […] - 2025-08-13 05:43:01
XBI, ALNY, INSM, INCY: Large Outflows Detected at ETF
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $202.3 million dollar outflow -- that's a 4.3% decrease week over week - 2025-08-12 11:55:54
Citigroup Raises Incyte (NASDAQ:INCY) Price Target to $103.00
Incyte (NASDAQ:INCY – Get Free Report) had its price objective lifted by equities researchers at Citigroup from $88.00 to $103.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Citigroup’s target price suggests a potential upside of 37.54% from the […] - 2025-08-01 04:32:55
Incyte Corporation (NASDAQ:INCY) Receives Consensus Recommendation of “Hold” from Analysts
Shares of Incyte Corporation (NASDAQ:INCY – Get Free Report) have earned a consensus rating of “Hold” from the eighteen research firms that are covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, twelve have given a hold recommendation and five have assigned a buy recommendation to the […] - 2025-08-01 03:04:43
Incyte Reaches Analyst Target Price
In recent trading, shares of Incyte Corporation (Symbol: INCY) have crossed above the average analyst 12-month target price of $76.09, changing hands for $77.38/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on v - 2025-07-30 10:12:59
Mutual of America Capital Management LLC Sells 478 Shares of Incyte Corporation (NASDAQ:INCY)
Mutual of America Capital Management LLC lessened its stake in Incyte Corporation (NASDAQ:INCY – Free Report) by 2.5% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 18,719 shares of the biopharmaceutical company’s stock after selling 478 shares during the quarter. […] - 2025-07-22 08:02:58
Incyte Corporation (NASDAQ:INCY) Shares Sold by Ballentine Partners LLC
Ballentine Partners LLC trimmed its position in Incyte Corporation (NASDAQ:INCY – Free Report) by 12.2% during the 1st quarter, HoldingsChannel reports. The institutional investor owned 4,686 shares of the biopharmaceutical company’s stock after selling 649 shares during the quarter. Ballentine Partners LLC’s holdings in Incyte were worth $284,000 at the end of the most recent […] - 2025-07-17 05:12:56
Cerity Partners LLC Has $8.04 Million Stock Position in Incyte Corporation (NASDAQ:INCY)
Cerity Partners LLC lifted its holdings in shares of Incyte Corporation (NASDAQ:INCY – Free Report) by 103.5% in the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 132,703 shares of the biopharmaceutical company’s stock after buying an additional 67,495 shares during the period. Cerity Partners LLC owned […] - 2025-07-16 05:40:51
Incyte (NASDAQ:INCY) Price Target Cut to $67.00 by Analysts at JPMorgan Chase & Co.
Incyte (NASDAQ:INCY – Get Free Report) had its price objective decreased by equities research analysts at JPMorgan Chase & Co. from $68.00 to $67.00 in a report released on Monday,Benzinga reports. The firm currently has a “neutral” rating on the biopharmaceutical company’s stock. JPMorgan Chase & Co.‘s price objective would suggest a potential downside of […] - 2025-07-16 04:26:52
Sheila A. Denton Sells 599 Shares of Incyte Corporation (NASDAQ:INCY) Stock
Incyte Corporation (NASDAQ:INCY – Get Free Report) EVP Sheila A. Denton sold 599 shares of the company’s stock in a transaction that occurred on Wednesday, July 2nd. The shares were sold at an average price of $68.61, for a total value of $41,097.39. Following the completion of the sale, the executive vice president owned 26,504 […] - 2025-07-09 06:12:52
Incyte Corporation (NASDAQ:INCY) EVP Barry P. Flannelly Sells 10,903 Shares of Stock
Incyte Corporation (NASDAQ:INCY – Get Free Report) EVP Barry P. Flannelly sold 10,903 shares of the stock in a transaction that occurred on Thursday, July 3rd. The shares were sold at an average price of $68.15, for a total transaction of $743,039.45. Following the sale, the executive vice president directly owned 39,744 shares of the […] - 2025-07-08 06:54:44
Incyte Corporation (NASDAQ:INCY) EVP Sells $587,248.55 in Stock
Incyte Corporation (NASDAQ:INCY – Get Free Report) EVP Vijay K. Iyengar sold 8,617 shares of the company’s stock in a transaction dated Thursday, July 3rd. The stock was sold at an average price of $68.15, for a total transaction of $587,248.55. Following the completion of the sale, the executive vice president directly owned 37,701 shares […] - 2025-07-08 06:20:54
Incyte Corporation (NASDAQ:INCY) Shares Sold by Vontobel Holding Ltd.
Vontobel Holding Ltd. trimmed its holdings in Incyte Corporation (NASDAQ:INCY – Free Report) by 16.8% in the first quarter, Holdings Channel.com reports. The institutional investor owned 7,875 shares of the biopharmaceutical company’s stock after selling 1,592 shares during the quarter. Vontobel Holding Ltd.’s holdings in Incyte were worth $477,000 as of its most recent filing […] - 2025-07-08 04:46:50
Sumitomo Mitsui Trust Group Inc. Purchases 25,844 Shares of Incyte Corporation (NASDAQ:INCY)
Sumitomo Mitsui Trust Group Inc. increased its position in shares of Incyte Corporation (NASDAQ:INCY – Free Report) by 5.8% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 473,186 shares of the biopharmaceutical company’s stock after purchasing an additional 25,844 shares […] - 2025-07-03 05:25:07
Incyte Corporation (NASDAQ:INCY) Shares Purchased by Chevy Chase Trust Holdings LLC
Chevy Chase Trust Holdings LLC raised its stake in Incyte Corporation (NASDAQ:INCY – Free Report) by 0.4% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 84,241 shares of the biopharmaceutical company’s stock after purchasing an additional 334 shares during the quarter. […] - 2025-06-27 05:36:52
Janney Montgomery Scott LLC Boosts Stock Position in Incyte Corporation (NASDAQ:INCY)
Janney Montgomery Scott LLC grew its stake in Incyte Corporation (NASDAQ:INCY – Free Report) by 10.2% in the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 29,793 shares of the biopharmaceutical company’s stock after purchasing an additional 2,746 shares during the period. Janney Montgomery Scott LLC’s holdings in Incyte were worth $1,804,000 as of its […] - 2025-06-27 04:26:49
State of Alaska Department of Revenue Purchases 590 Shares of Incyte Corporation (NASDAQ:INCY)
State of Alaska Department of Revenue lifted its position in shares of Incyte Corporation (NASDAQ:INCY – Free Report) by 3.2% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 18,824 shares of the biopharmaceutical company’s stock after acquiring an additional 590 shares […] - 2025-06-26 05:56:50
Kentucky Retirement Systems Insurance Trust Fund Makes New Investment in Incyte Corporation (NASDAQ:INCY)
Kentucky Retirement Systems Insurance Trust Fund bought a new stake in Incyte Corporation (NASDAQ:INCY – Free Report) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 4,624 shares of the biopharmaceutical company’s stock, valued at approximately $280,000. A number […] - 2025-06-26 05:03:09
Incyte Corporation (NASDAQ:INCY) Shares Acquired by Wealth Enhancement Advisory Services LLC
Wealth Enhancement Advisory Services LLC lifted its position in shares of Incyte Corporation (NASDAQ:INCY – Free Report) by 66.5% during the 1st quarter, HoldingsChannel.com reports. The fund owned 79,735 shares of the biopharmaceutical company’s stock after acquiring an additional 31,851 shares during the quarter. Wealth Enhancement Advisory Services LLC’s holdings in Incyte were worth $4,828,000 […] - 2025-06-26 04:30:52
Assenagon Asset Management S.A. Has $536,000 Stock Position in Incyte Corporation (NASDAQ:INCY)
Assenagon Asset Management S.A. raised its position in Incyte Corporation (NASDAQ:INCY – Free Report) by 37.6% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 8,846 shares of the biopharmaceutical company’s stock after acquiring an additional 2,418 shares during the period. […] - 2025-06-20 04:54:50
Incyte Corporation (NASDAQ:INCY) Shares Sold by Exchange Traded Concepts LLC
Exchange Traded Concepts LLC lowered its position in shares of Incyte Corporation (NASDAQ:INCY – Free Report) by 41.5% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 18,117 shares of the biopharmaceutical company’s stock after selling 12,867 shares during the period. Exchange Traded Concepts […] - 2025-06-19 05:43:03
Fifth Third Bancorp Has $551,000 Holdings in Incyte Corporation (NASDAQ:INCY)
Fifth Third Bancorp raised its holdings in Incyte Corporation (NASDAQ:INCY – Free Report) by 2.0% during the 1st quarter, Holdings Channel.com reports. The institutional investor owned 9,103 shares of the biopharmaceutical company’s stock after acquiring an additional 179 shares during the quarter. Fifth Third Bancorp’s holdings in Incyte were worth $551,000 at the end of […] - 2025-06-18 04:56:49
Incyte (NASDAQ:INCY) Raised to “Buy” at Stifel Nicolaus
Incyte (NASDAQ:INCY – Get Free Report) was upgraded by equities researchers at Stifel Nicolaus from a “hold” rating to a “buy” rating in a research report issued on Monday, MarketBeat reports. The brokerage currently has a $107.00 price objective on the biopharmaceutical company’s stock, up from their previous price objective of $75.00. Stifel Nicolaus’ price […] - 2025-06-18 02:22:54
Stocks Settle Higher on Possible De-Escalation of Israel-Iran War
The S&P 500 Index ($SPX ) (SPY ) Monday closed up +0.94%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.75%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +1.42%. June E-mini S&P futures (ESM25 ) are up +1.00%, and June E-mini Nasdaq futures... - 2025-06-17 13:23:43

iShares MSCI USA ESG Enhanced UCITS ETF USD (Dist) INCY holdings

DateNumber of INCY Shares HeldBase Market Value of INCY SharesLocal Market Value of INCY SharesChange in INCY Shares HeldChange in INCY Base ValueCurrent Price per INCY Share HeldPrevious Price per INCY Share Held
2025-10-01 (Wednesday)39,616USD 3,434,707USD 3,434,707
2025-09-30 (Tuesday)39,429USD 3,343,973INCY holding increased by 36274USD 3,343,9730USD 36,274 USD 84.81 USD 83.89
2025-09-29 (Monday)39,429INCY holding increased by 10USD 3,307,699INCY holding increased by 47748USD 3,307,69910USD 47,748 USD 83.89 USD 82.7
2025-09-26 (Friday)39,419INCY holding decreased by -524USD 3,259,951INCY holding decreased by -1794USD 3,259,951-524USD -1,794 USD 82.7 USD 81.66
2025-09-25 (Thursday)39,943INCY holding increased by 270USD 3,261,745INCY holding decreased by -77135USD 3,261,745270USD -77,135 USD 81.66 USD 84.16
2025-09-24 (Wednesday)39,673USD 3,338,880USD 3,338,880
2025-09-18 (Thursday)37,755INCY holding increased by 140USD 3,246,930INCY holding increased by 57178USD 3,246,930140USD 57,178 USD 86 USD 84.8
2025-09-17 (Wednesday)37,615INCY holding increased by 258USD 3,189,752INCY holding increased by 55500USD 3,189,752258USD 55,500 USD 84.8 USD 83.9
2025-09-16 (Tuesday)37,357USD 3,134,252INCY holding increased by 28391USD 3,134,2520USD 28,391 USD 83.9 USD 83.14
2025-09-15 (Monday)37,357USD 3,105,861USD 3,105,861
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of INCY by Blackrock for IE00BHZPJ890

Show aggregate share trades of INCY

DateActionQuantityMarket HighMarket LowLikely Trade PriceLikely Trade Value (Profit/Loss)Average Price previous trades
2025-09-29BUY10 83.890* 69.41
2025-09-26SELL-524 82.700* 69.34 Profit of 36,333 on sale
2025-09-25BUY270 81.660* 69.27
2025-09-18BUY140 86.000* 69.18
2025-09-17BUY258 84.800* 69.09
2025-09-11SELL-331 86.170* 68.91 Profit of 22,809 on sale
2025-09-10BUY57 86.250* 68.81
2025-09-09BUY78 85.600* 68.72
2025-08-27BUY40 84.840* 68.54
2025-08-21BUY10 86.530* 68.33
2025-08-19BUY30 85.460* 68.13
2025-07-21BUY5 67.380* 68.13
2025-07-18BUY235 67.860* 68.13
2025-07-17BUY30 68.940* 68.13
2025-07-16BUY437 69.230* 68.12
2025-07-15BUY330 68.250* 68.12
2025-07-03SELL-40 68.450* 68.12 Profit of 2,725 on sale
2025-07-02SELL-372 68.170* 68.12 Profit of 25,339 on sale
2025-06-30SELL-14 68.100* 68.12 Profit of 954 on sale
2025-06-27BUY24 68.370* 68.11
2025-06-26BUY10 70.810* 68.10
2025-06-25BUY24 67.550* 68.10
2025-06-24SELL-18 69.010* 68.10 Profit of 1,226 on sale
2025-06-17SELL-25 68.810* 68.09 Profit of 1,702 on sale
2025-06-13SELL-8 67.750* 68.07 Profit of 545 on sale
2025-06-12BUY15 69.220* 68.06
2025-06-06SELL-84 68.770* 68.03 Profit of 5,714 on sale
2025-06-05SELL-132 67.240* 68.03 Profit of 8,980 on sale
2025-06-04SELL-145 67.420* 68.04 Profit of 9,865 on sale
2025-06-03BUY30 67.110* 68.04
2025-06-02SELL-8 65.310* 68.06 Profit of 545 on sale
2025-05-30BUY15,206 65.060* 68.09
2025-05-29SELL-18 66.040* 68.10 Profit of 1,226 on sale
2025-05-28SELL-12 64.930* 68.12 Profit of 817 on sale
2025-05-23SELL-54 64.245* 68.20 Profit of 3,683 on sale
2025-05-22BUY3 64.510* 68.23
2025-05-21SELL-15 64.780* 68.26 Profit of 1,024 on sale
2025-05-20BUY66 65.300* 68.28
2025-05-16SELL-27 63.310* 68.35 Profit of 1,845 on sale
2025-05-15BUY3 62.760* 68.40
2025-05-14BUY54 61.160* 68.45
2025-05-13BUY194 60.810* 68.51
2025-05-12BUY159 60.850* 68.57
2025-05-09BUY51 58.980* 68.65
2025-05-08SELL-48 59.730* 68.72 Profit of 3,299 on sale
2025-05-07BUY141 59.550* 68.80
2025-05-06BUY33 59.610* 68.88
2025-05-02SELL-6 62.530* 68.99 Profit of 414 on sale
2025-05-01SELL-3 62.030* 69.04 Profit of 207 on sale
2025-04-28SELL-404 59.520* 69.26 Profit of 27,980 on sale
2025-04-25SELL-6 59.160* 69.35 Profit of 416 on sale
2025-04-24SELL-93 58.970* 69.44 Profit of 6,458 on sale
2025-04-23SELL-33 58.000* 69.54 Profit of 2,295 on sale
2025-04-22SELL-21 57.380* 69.65 Profit of 1,463 on sale
2025-04-16SELL-117 57.730* 70.09 Profit of 8,201 on sale
2025-04-11BUY57 56.870* 70.44
2025-04-10BUY18 55.170* 70.59
2025-04-09BUY30 58.860* 70.70
2025-04-08SELL-87 56.970* 70.84 Profit of 6,163 on sale
2025-04-07BUY57 60.290* 70.94
2025-04-04BUY129 60.580* 71.05
2025-04-02BUY51 62.330* 71.14
2025-04-01BUY24 60.910* 71.24
2025-03-31SELL-129 60.550* 71.35 Profit of 9,205 on sale
2025-03-28SELL-12 60.600* 71.47 Profit of 858 on sale
2025-03-26BUY3 61.260* 71.69
2025-03-25BUY9 62.080* 71.80
2025-03-24BUY18 62.780* 71.90
2025-03-21BUY462 61.920* 72.01
2025-03-20BUY6 60.580* 72.14
2025-03-19SELL-87 60.340* 72.27 Profit of 6,287 on sale
2025-03-17SELL-6 62.010* 72.53 Profit of 435 on sale
2025-03-14SELL-12 67.860* 72.59 Profit of 871 on sale
2025-03-13SELL-3 67.710* 72.64 Profit of 218 on sale
2025-03-12SELL-15 67.730* 72.70 Profit of 1,091 on sale
2025-03-11BUY3 68.070* 72.76
2025-03-06BUY186 70.090* 72.84
2025-03-05SELL-15 69.810* 72.88 Profit of 1,093 on sale
2025-03-03BUY9 70.260* 72.95
2025-02-28BUY63 73.500* 72.95
2025-02-27SELL-60 73.180* 72.94 Profit of 4,377 on sale
2025-02-26SELL-759 74.300* 72.93 Profit of 55,351 on sale
2025-02-25SELL-51 74.400* 72.91 Profit of 3,718 on sale
2025-02-24BUY75 74.010* 72.89
2025-02-21BUY39 72.110* 72.90
2025-02-20BUY6 71.380* 72.92
2025-02-19BUY6 70.160* 72.96
2025-02-18SELL-33 71.270* 72.99 Profit of 2,409 on sale
2025-02-14BUY9 70.420* 73.07
2025-02-13SELL-6 70.010* 73.12 Profit of 439 on sale
2025-02-12SELL-114 69.050* 73.18 Profit of 8,343 on sale
2025-02-06BUY15 74.950* 73.33
2025-02-05SELL-45 75.260* 73.30 Profit of 3,298 on sale
2025-02-03BUY5 73.740* 73.28
2025-01-30SELL-63 73.770* 73.25 Profit of 4,615 on sale
2025-01-28SELL-39 73.150* 73.24 Profit of 2,857 on sale
2025-01-27BUY18 72.640* 73.26
2025-01-24BUY33 72.590* 73.27
2025-01-23BUY33 72.530* 73.28
2024-12-09BUY6 72.110* 73.33
2024-12-06BUY93 75.920* 73.27
2024-12-04BUY69 74.620* 73.20
2024-12-03BUY39 72.030* 73.23
2024-12-02BUY90 73.240* 73.23
2024-11-29BUY9 74.590* 73.20
2024-11-27BUY3 75.450* 73.08
2024-11-26SELL-102 74.800* 73.04 Profit of 7,450 on sale
2024-11-25BUY18 73.520* 73.02
2024-11-22SELL-5 71.720* 73.06 Profit of 365 on sale
2024-11-21BUY126 70.390* 73.13
2024-11-19SELL-27 70.560* 73.28 Profit of 1,978 on sale
2024-11-18BUY60 76.970* 73.16
2024-11-12BUY3 80.580* 72.92
2024-11-08BUY9 83.380* 71.87
2024-11-08BUY9 83.380* 71.87
2024-11-07BUY231 82.340* 71.06
2024-11-07BUY231 82.340* 71.06
2024-11-06BUY6 80.950* 70.24
2024-11-06BUY6 80.950* 70.24
2024-11-05SELL-15 77.280* 69.60 Profit of 1,044 on sale
2024-11-05SELL-15 77.280* 69.60 Profit of 1,044 on sale
2024-11-04SELL-108 75.750* 68.98 Profit of 7,450 on sale
2024-11-04SELL-108 75.750* 68.98 Profit of 7,450 on sale
2024-11-01SELL-30 76.130* 68.19 Profit of 2,046 on sale
2024-11-01SELL-30 76.130* 68.19 Profit of 2,046 on sale
2024-10-31BUY17 74.120* 67.44
2024-10-31BUY17 74.120* 67.44
2024-10-30SELL-114 73.930* 66.52 Profit of 7,583 on sale
2024-10-30SELL-114 73.930* 66.52 Profit of 7,583 on sale
2024-10-29SELL-108 73.600* 65.34 Profit of 7,057 on sale
2024-10-29SELL-108 73.600* 65.34 Profit of 7,057 on sale
2024-10-28BUY9 65.690* 65.27
2024-10-28BUY9 65.690* 65.27
2024-10-25BUY192 65.070* 65.32
2024-10-25BUY192 65.070* 65.32
2024-10-24BUY24 65.240* 65.34
2024-10-24BUY24 65.240* 65.34
2024-10-23SELL-4 65.170* 65.43 Profit of 262 on sale
2024-10-23SELL-4 65.170* 65.43 Profit of 262 on sale
2024-10-22BUY21 65.590* 65.27
2024-10-22BUY21 65.590* 65.27
2024-10-21SELL-210 65.270* 0.00
2024-10-21SELL-210 65.270* 0.00
Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of INCY

DateShorted VolumeShort Exempt VolumeTotal Shares Traded% Shorted
2025-09-19321,923395451,11071.4%
2025-09-18244,9471,423469,74752.1%
2025-09-17277,858779546,95350.8%
2025-09-16359,781946576,37962.4%
2025-09-15347,4534582,22859.7%
2025-09-12353,0400631,53455.9%
2025-09-11448,7333,894739,70160.7%
2025-09-10490,727248671,93273.0%
2025-09-09515,3951,822682,79175.5%
2025-09-08308,184119479,82864.2%
2025-09-05256,7192,505512,04950.1%
2025-09-04422,6241,507834,71750.6%
2025-09-03381,6797,777624,92261.1%
2025-09-02547,12015,396816,26767.0%
2025-08-29148,294262304,42748.7%
2025-08-28164,0080347,48047.2%
2025-08-27248,926453513,40148.5%
2025-08-26365,1306709,32051.5%
2025-08-25478,1301,306642,31974.4%
2025-08-22344,3522,023596,30157.7%
2025-08-21198,7294,881335,30159.3%
2025-08-20351,6993,977555,34563.3%
2025-08-19343,1103,146574,32859.7%
2025-08-18366,1244,996653,10356.1%
2025-08-15480,8858,035625,79776.8%
2025-08-14593,55436,654806,06873.6%
2025-08-13845,18198,1601,257,50367.2%
2025-08-12462,89642,208678,68968.2%
2025-08-11385,211696595,89264.6%
2025-08-08248,925738426,18758.4%
2025-08-07268,864929420,48663.9%
2025-08-06554,642891731,48475.8%
2025-08-05361,6872,092623,87958.0%
2025-08-04338,0051,464519,15065.1%
2025-08-01414,814828572,87972.4%
2025-07-31570,8456,148777,41773.4%
2025-07-30471,30314,166881,19453.5%
2025-07-29966,64010,5811,593,70160.7%
2025-07-28382,23662625,51061.1%
2025-07-25216,96749422,99051.3%
2025-07-24348,27623528,51765.9%
2025-07-23297,903583487,29761.1%
2025-07-22267,987172446,48960.0%
2025-07-21223,626380406,72955.0%
2025-07-18241,218108471,58951.2%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.